GABRQ antibody (AA 211-320) (Cy3)

Catalog No. ABIN1412949

This anti-GABRQ antibody is a Rabbit Polyclonal antibody detecting GABRQ in IF (cc) and IF (p). Suitable for Human.

Quick Overview for GABRQ antibody (AA 211-320) (Cy3) (ABIN1412949)

Target: GABRQ (gamma-aminobutyric Acid (GABA) Receptor, theta (GABRQ))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This GABRQ antibody is conjugated to Cy3

Application: Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Product Details anti-GABRQ Antibody (Cy3)

Binding Specificity: AA 211-320

Predicted Reactivity: Human,Mouse,Rat,Rabbit

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human GABRQ/GABA A Receptor ta

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for GABRQ

Target: GABRQ (gamma-aminobutyric Acid (GABA) Receptor, theta (GABRQ))

Alternative Name: GABRQ/GABA A Receptor theta

Background:

Synonyms: gamma aminobutyric acid GABA receptor, theta, Gamma aminobutyric acid receptor theta subunit precursor, gamma aminobutyric acid receptor, theta, THETA, GBRT_HUMAN.

Background: Gamma-aminobutyric acid type A (GABAA) receptors mediate inhibitory neurotransmission in the mammalian central nervous system. The receptor exists as a pentameric ion channel composed by heteromeric combinations of alpha, beta, gamma, delta, epsilon, theta, or pi subunits. Only specific subunit combinations produce viable receptors, while others never translocate to the cell surface from the ER where they are synthesized, and subsequently degraded. The theta subunit forms a receptor in combination with alpha3 subunits in monoaminergic cell groups. These receptors, found especially in the septum, preoptic areas, hypothalamic nuclei, amygdala and thalamus, likely have unique pharmacological properties linked to their expression in this particular cell type and not cholinergic cell groups, and may play a role in opiate withdrawl symptoms.